tirzepatide phase 2 Once-weekly versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type diabetes (SURPASS-3): a randomised, open-label, parallel-group, 3 trial Tirzepatide for type 1 diabetes

Hydrazone linker Hydrazone, an acid-labile group, is used as a cleavable linker that releases free drug through hydrolysis once an ADC is transported to acidic endosomes (pH 5.06.0) and lysosomes (pH about 4.8) (Fig

E.UferC.KuhnH.BorchertA

* This is a higher level than in previous guidance (75 mmol/mol) due to the availability of more medicines to manage hyperglycaemia 12 Treatment options at Step 2 (typically added to metformin) include: Empagliflozin (oral, funded with Special Authority see: Initiating funded treatment and Prescribing empagliflozin), taken either as separate metformin and empagliflozin tablets, or a combination empagliflozin + metformin formulation Dulaglutide (injectable, funded with Special Authority see: Initiating funded treatment and Prescribing dulaglutide) Liraglutide (injectable, funded with Special Authority see: Liraglutide

CrossRef Reshaping the Future of MASLD - From Pathophysiological Mechanisms to New Therapeutic Horizons Dimitrios Patoulias, Manfredi Rizzo Current Pharmaceutical Design .2026

We take the time to understand your individual needs and tailor our treatment approach accordingly